Four year data for Wegovy (semaglutide) in obesity presented at ECO meeting and published in Nature
At the European Congress on Obesity in Venice, investigators unveiled results from an analysis published in Nature Medicine evaluating Wegovy’s weight loss benefits over four years
With this new four-year data in hand, Novo Nordisk can make a case for its popular obesity med Wegovy to be used as a long-term treatment.
In more than 17,000 non-diabetic overweight and obese patients who suffered from preexisting heart disease, patients lost an average of nearly 10% of their total body weight after 65 weeks on Wegovy, the investigators said. Patients sustained the results until the end of four years when their average weight loss came to 10.2%.
See- -Published: 13 May 2024."Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial"; Donna H. Ryan, Ildiko Lingvay, John Deanfield, Steven E. Kahn, Eric Barros, Bartolome Burguera, Helen M. Colhoun, Cintia Cercato, Dror Dicker, Deborah B. Horn, G. Kees Hovingh, Ole Kleist Jeppesen, Alexander Kokkinos, A. Michael Lincoff, Sebastian M. Meyhöfer, Tugce Kalayci Oral, Jorge Plutzky, André P. van Beek, John P. H. Wilding & Robert F. Kushner Nature Medicine (2024). Nat Med (2024). https://doi.org/10.1038/s41591-024-02996-7.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins